Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA
Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA.
J Clin Microbiol. 2020 Feb 24;58(3). doi: 10.1128/JCM.01739-19.
INTRODUCTIONWith established applications of next-generation sequencing in inherited diseases and oncology, clinical laboratories are evaluating the use of metagenomics for identification of infectious agents directly from patient samples, to aid in the diagnosis of infections. Metagenomic next-generation sequencing for infectious diseases promises an unbiased approach to detection of microbes that does not depend on growth in culture or the targeting of specific pathogens. However, the issues of contamination, interpretation of results, selection of databases used for analysis, and prediction of antimicrobial susceptibilities from sequencing data remain challenges. In this Point-Counterpoint, Steve Miller and Charles Chiu discuss the pros of using direct metagenomic sequencing, while Kyle Rodino and Melissa Miller argue for the use of caution.
引言
随着下一代测序技术在遗传病和肿瘤学中的应用得到确立,临床实验室正在评估直接从患者样本中使用宏基因组学来鉴定病原体的方法,以帮助诊断感染。用于传染病的宏基因组下一代测序有望提供一种不依赖于培养或针对特定病原体的微生物检测的无偏方法。然而,污染、结果解释、用于分析的数据库选择以及从测序数据预测抗菌药物敏感性等问题仍然是挑战。在这篇观点交锋中,Steve Miller 和 Charles Chiu 讨论了使用直接宏基因组测序的优点,而 Kyle Rodino 和 Melissa Miller 则对使用该方法提出了谨慎的看法。